

Cuban Interferon Proven Effective Against COVID-19

Data shows that only 5.5% of patients treated with Heberon developed serious complications

By Orfilio Peláez

Global Research, May 14, 2020

Granma 12 May 2020

Region: <u>Latin America & Caribbean</u>
Theme: Intelligence, Science and Medicine

Since the appearance, March 11, of the first cases of COVID-19 in Cuba, the country's Ministry of Public Health (Minsap) has reported that the inclusion of Recombinant Human Interferon Alpha 2b in treatment protocols for these patients has shown positive results.

Details on the effectiveness of the product were presented by Dr. Eulogio Pimentel Vázquez, director of the Center for Genetic Engineering and Biotechnology (CIGB), affiliated with the BioCubaFarma Enterprise Group, where the medication was first produced in the late 1980s.

"The strength of the Cuban health system, and its close ties with the biotechnology and pharmaceutical industries, in our social system that prioritizes the people's health, makes possible the medication's availability for all Cubans."

According to Dr. Pimentel, in accordance with the Minsap treatment protocol, this product, in combination with other drugs, is used as soon as a case is confirmed, and not with patients in serious or critical condition.

Data released April 14 shows that 93.4% of patients testing positive for SARS-COV-2 had been treated with Heberon (the commercial name of Recombinant Human Interferon Alpha 2b). Only 5.5% reached serious condition. The mortality rate reported by Minsap on that date was 2.7%, while for patients with whom the drug was used, the rate was 0.9%. On this same date, on the international level, 15 to 20% of patients were reported in serious condition, while the mortality rate was over 6%.

"The data shows that the protocol in our country is effective, and interferon plays a key role in these results."

Referring to the medication's use around the world, the doctor noted that important reports of preclinical and clinical evidence have appeared in several countries. One recent scientific article refers to a study conducted in Wuhan, China, regarding its use with medical personnel. Of the individuals included in the study, 2,944 received the drug and 3,387 did not. Fifty percent of those not treated contracted the disease, while there were no cases identified among those who benefited from Cuban interferon.

At this time, more than 80 countries have expressed interest in acquiring Heberon, reflecting confidence in its usefulness in confronting the pandemic.

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from CIGB

The original source of this article is <u>Granma</u> Copyright © <u>Orfilio Peláez</u>, <u>Granma</u>, 2020

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Orfilio Peláez

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca